​A Phase 3, Open-Label, Multicentre Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography BC of Suspected Coronary Artery Disease

​This is a Phase 3, prospective, open-label, international, multicentre study of Flurpiridaz (18F) Injection for PET MPI in patients referred for ICA because of suspected CAD.

Principal Investigator: Dr. Medhat Osman

To learn more about AURORA and how you can join contact our research office at (314) 289-7690.

This study is funded by the Foundation through GE Healthcare